174 related articles for article (PubMed ID: 30349294)
21. Asparagine synthetase is partially localized to the plasma membrane and upregulated by L-asparaginase in U937 cells.
He Y; Li B; Luo C; Shen S; Chen J; Xue H; Tang J; Gu L
J Huazhong Univ Sci Technolog Med Sci; 2011 Apr; 31(2):159-163. PubMed ID: 21505976
[TBL] [Abstract][Full Text] [Related]
22. A proposal for a prognostic index for non-nasal type natural killer/T cell lymphoma after asparaginase-based treatment.
Chen Z; Fang X; Huang H; Wang Z; Hong H; Chen M; Ren Q; Yao Y; Zhang L; Tian Y; Lin S; Lin T
Ann Hematol; 2020 Dec; 99(12):2811-2819. PubMed ID: 32975588
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL.
Touzart A; Lengliné E; Latiri M; Belhocine M; Smith C; Thomas X; Spicuglia S; Puthier D; Pflumio F; Leguay T; Graux C; Chalandon Y; Huguet F; Leprêtre S; Ifrah N; Dombret H; Macintyre E; Hunault M; Boissel N; Asnafi V
Clin Cancer Res; 2019 Apr; 25(8):2483-2493. PubMed ID: 30659025
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic tumor sensitivity to plasma L-asparagine starvation.
Dufour E; Gay F; Aguera K; Scoazec JY; Horand F; Lorenzi PL; Godfrin Y
Pancreas; 2012 Aug; 41(6):940-8. PubMed ID: 22513289
[TBL] [Abstract][Full Text] [Related]
25. L-asparaginase anti-tumor activity in pancreatic cancer is dependent on its glutaminase activity and resistance is mediated by glutamine synthetase.
Blachier J; Cleret A; Guerin N; Gil C; Fanjat JM; Tavernier F; Vidault L; Gallix F; Rama N; Rossignol R; Piedrahita D; Andrivon A; Châlons-Cottavoz M; Aguera K; Gay F; Horand F; Laperrousaz B
Exp Cell Res; 2023 May; 426(2):113568. PubMed ID: 36967104
[TBL] [Abstract][Full Text] [Related]
26. Asparagine Synthetase Is Highly Expressed at Baseline in the Pancreas Through Heightened PERK Signaling.
Mukherjee A; Ahmed N; Rose FT; Ahmad AN; Javed TA; Wen L; Bottino R; Xiao X; Kilberg MS; Husain SZ
Cell Mol Gastroenterol Hepatol; 2020; 9(1):1-13. PubMed ID: 31421261
[TBL] [Abstract][Full Text] [Related]
27. Identification of a cytogenetic and molecular subgroup of acute myeloid leukemias showing sensitivity to L-Asparaginase.
Bertuccio SN; Serravalle S; Astolfi A; Lonetti A; Indio V; Leszl A; Pession A; Melchionda F
Oncotarget; 2017 Dec; 8(66):109915-109923. PubMed ID: 29299118
[TBL] [Abstract][Full Text] [Related]
28. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
Lorenzi PL; Reinhold WC; Rudelius M; Gunsior M; Shankavaram U; Bussey KJ; Scherf U; Eichler GS; Martin SE; Chin K; Gray JW; Kohn EC; Horak ID; Von Hoff DD; Raffeld M; Goldsmith PK; Caplen NJ; Weinstein JN
Mol Cancer Ther; 2006 Nov; 5(11):2613-23. PubMed ID: 17088436
[TBL] [Abstract][Full Text] [Related]
29. A five
Vittayawacharin P; Khuhapinant A
Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594
[TBL] [Abstract][Full Text] [Related]
30. Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients.
Abbatiello SE; Pan YX; Zhou M; Wayne AS; Veenstra TD; Hunger SP; Kilberg MS; Eyler JR; Richards NG; Conrads TP
J Proteomics; 2008 Apr; 71(1):61-70. PubMed ID: 18541474
[TBL] [Abstract][Full Text] [Related]
31. Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type.
Nishimura A; Yokoyama K; Naruto T; Yamagishi C; Imamura T; Nakazono H; Kimura S; Ito M; Sagisaka M; Tanaka Y; Piao J; Namikawa Y; Yanagimachi M; Isoda T; Kanai A; Matsui H; Isobe T; Sato-Otsubo A; Higuchi N; Takada A; Okuno H; Saito S; Karakawa S; Kobayashi S; Hasegawa D; Fujisaki H; Hasegawa D; Koike K; Koike T; Rai S; Umeda K; Sano H; Sekinaka Y; Ogawa A; Kinoshita A; Shiba N; Miki M; Kimura F; Nakayama H; Nakazawa Y; Taga T; Taki T; Adachi S; Manabe A; Koh K; Ishida Y; Takita J; Ishikawa F; Goto H; Morio T; Mizutani S; Tojo A; Takagi M
Sci Adv; 2023 Dec; 9(50):eadj4407. PubMed ID: 38091391
[TBL] [Abstract][Full Text] [Related]
32. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia.
Fine BM; Kaspers GJ; Ho M; Loonen AH; Boxer LM
Cancer Res; 2005 Jan; 65(1):291-9. PubMed ID: 15665306
[TBL] [Abstract][Full Text] [Related]
33. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment 14-3-3 epsilon level is predictive for advanced extranodal NK/T cell lymphoma therapeutic response to asparaginase-based chemotherapy.
Qiu Y; Zhou Z; Li Z; Lu L; Li L; Li X; Wang X; Zhang M
Proteomics Clin Appl; 2017 Mar; 11(3-4):. PubMed ID: 27774748
[TBL] [Abstract][Full Text] [Related]
35. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines.
Lorenzi PL; Llamas J; Gunsior M; Ozbun L; Reinhold WC; Varma S; Ji H; Kim H; Hutchinson AA; Kohn EC; Goldsmith PK; Birrer MJ; Weinstein JN
Mol Cancer Ther; 2008 Oct; 7(10):3123-8. PubMed ID: 18852115
[TBL] [Abstract][Full Text] [Related]
36. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.
Panosyan EH; Wang Y; Xia P; Lee WN; Pak Y; Laks DR; Lin HJ; Moore TB; Cloughesy TF; Kornblum HI; Lasky JL
Mol Cancer Res; 2014 May; 12(5):694-702. PubMed ID: 24505127
[TBL] [Abstract][Full Text] [Related]
37. Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T-cell lymphoma in children and adolescents.
Zhen Z; Huang H; Lin T; Li Z; Zhen X; Xia Z; Zhu J; Lu S; Sun F; Wang J; Huang J; Sun X
Pediatr Blood Cancer; 2021 May; 68(5):e28901. PubMed ID: 33484107
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms.
Apfel V; Begue D; Cordo' V; Holzer L; Martinuzzi L; Buhles A; Kerr G; Barbosa I; Naumann U; Piquet M; Ruddy D; Weiss A; Ferretti S; Almeida R; Bonenfant D; Tordella L; Galli GG
ACS Pharmacol Transl Sci; 2021 Feb; 4(1):327-337. PubMed ID: 33615182
[TBL] [Abstract][Full Text] [Related]
39. [Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences].
Bakos A; Szomor Á; Schneider T; Miltényi Z; Marton I; Borbényi Z; Pammer J; Krenács L; Bagdi E; Piukovics K
Orv Hetil; 2017 Oct; 158(41):1635-1641. PubMed ID: 29025287
[TBL] [Abstract][Full Text] [Related]
40. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.
Haverkos BM; Pan Z; Gru AA; Freud AG; Rabinovitch R; Xu-Welliver M; Otto B; Barrionuevo C; Baiocchi RA; Rochford R; Porcu P
Curr Hematol Malig Rep; 2016 Dec; 11(6):514-527. PubMed ID: 27778143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
